SLC6A6 and dilated cardiomyopathy: Taken together, our findings of trastuzumab induced down-regulation of SLC6A6 in human iPSC-derived cardiomyocytes, and the reported phenotypes of dilated cardiomyopathy and altered metabolism in Slc6a6 knock-out mice provide a potential mechanism towards trastuzumab related cardiotoxicity.